Egypt’s Parkville Pharmaceuticals gets investment from Proparco, Adenia and DEG

Parkville Pharmaceuticals, a leading, fast-growing Egyptian pharmaceutical and cosmeceutical company, has secured a majority investment from Proparco, a pan-African private equity firm, Adenia and Germany’s development finance institution DEG, positioning the leading cosmeceutical manufacturer for accelerated regional expansion. 

Majority investment in Egyptian Pharma
The transaction strengthens Egypt’s domestic pharmaceutical manufacturing capacity, supports import substitution and enhances access to affordable, high-quality healthcare and personal care products across key markets.

The investor consortium, led by Adenia as majority shareholder, is acquiring a controlling stake from Admaius Capital Partners and the company’s founders, Mahmoud Farrag and Sherif Bassiouny. Admaius will fully exit its investment, while the founders will retain minority stakes and remain involved in the business.

Backing a fast-growing Egyptian industrial champion
Founded in 2008 and headquartered in Cairo, Parkville Pharmaceuticals develops, manufactures and distributes dermo-cosmetic products, dietary supplements and muscle relaxants. 

Its portfolio includes well-known brands such as Starville, Strongville, Bobai, Glamy Lab and Shaan, which have established strong market positions across key therapeutic and personal care segments in Egypt.

Since 2023, Parkville has operated its own production facility in Alexandria and exports to multiple regional markets. The company combines competitive pricing with a broad distribution network spanning pharmacies, hospitals and e-commerce platforms, positioning it as a credible local alternative to international brands.

Catalyzing the next phase of expansion
For Adenia, the deal marks its first investment in Egypt and reinforces its strategy of backing high-potential African champions. The firm plans to support Parkville’s next growth phase by expanding its product portfolio, strengthening industrial and digital capabilities and accelerating regional expansion.

Proparco views the investment as aligned with its 2023–2027 strategy to promote structural economic transformation and stronger local value chains. The transaction supports import substitution by boosting domestic cosmeceutical production and enhances access to affordable healthcare products. “Parkville embodies Egypt’s industrial dynamism and the capacity of local champions to compete effectively,” said Tibor Asboth, Head of Private Equity Africa and Middle East at Proparco.

The acquisition underscores growing collaboration between African private equity and European development finance institutions to scale resilient, locally rooted businesses and advance economic sovereignty across the continent.